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Background: Crohn’s disease (CD) is a lifelong, relapsing and remitting inflammatory condition of the intestine.
Medical imaging is crucial for diagnosis, phenotyping, activity assessment and detecting complications. Diverse small
bowel imaging tests are available but a standard algorithm for deployment is lacking. Many hospitals employ tests that
impart ionising radiation, of particular concern to this young patient population. Magnetic resonance enterography
(MRE) and small bowel ultrasound (USS) are attractive options, as they do not use ionising radiation. However, their
comparative diagnostic accuracy has not been compared in large head to head trials. METRIC aims to compare the
diagnostic efficacy, therapeutic impact and cost effectiveness of MRE and USS in newly diagnosed and relapsing CD.
Methods: METRIC (ISRCTN03982913) is a multicentre, non-randomised, single-arm, prospective comparison study. Two
patient cohorts will be recruited; those newly diagnosed with CD, and those with suspected relapse. Both will undergo
MRE and USS in addition to other imaging tests performed as part of clinical care. Strict blinding protocols will be
enforced for those interpreting MRE and USS. The Harvey Bradshaw index, C-reactive protein and faecal calprotectin will
be collected at recruitment and 3 months, and patient experience will be assessed via questionnaires. A multidisciplinary
consensus panel will assess all available clinical and imaging data up to 6 months after recruitment of each patient and
will define the standard of reference for the presence, localisation and activity of disease against which the diagnostic
accuracy of MRE and USS will be judged. Diagnostic impact of MRE and USS will be evaluated and cost effectiveness will
be assessed. The primary outcome measure is the difference in per patient sensitivity between MRE and USS for the
correct identification and localisation of small bowel CD.
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Discussion: The trial is open at 5 centres with 46 patients recruited. We highlight the importance of stringent blinding
protocols in order to delineate the true diagnostic accuracy of both imaging tests and discuss the difficulties of diagnostic
accuracy studies in the absence of a single standard of reference, describing our approach utilising a consensus panel
whilst minimising incorporation bias.
Trial registration: METRIC - ISRCTN03982913 – 05.11.13.
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Crohn’s disease (CD) is an inflammatory condition, with a
wide spectrum of intestinal manifestations ranging from
superficial bowel wall ulceration to deep penetrating
disease, characterised by fistulae and abscesses. Over
time, repeated inflammatory insults can result in the
development of fibrosis and stricture formation. It affects
200,000 people in the UK (around 1 in 500), most are
young (diagnosed < 35 years) and the costs of direct
medical care in the UK exceed £500 million [1]. A range
of potentially toxic medical treatment options, such as
immune-modulators, or targeted surgical interventions are
currently employed in disease management. The optimal
treatment strategy requires accurate assessment of disease
presence, extent, activity and complications. CD typically
affects the small bowel, most of which is beyond the reach
of conventional colonoscopy. Small bowel imaging there-
fore plays a vital role in diagnosing and phenotyping CD,
thereafter assessing disease activity and complications.
At present there is no single imaging modality that has
been proven universally superior in either suspected or
established CD. A plethora of small bowel investigations
are currently performed within the NHS, approximately
100,000 each year, including Barium fluoroscopy (BaF),
Computerised Tomography (CT), Ultrasound (USS) and
Magnetic Resonance Enterography (MRE). According to
a UK survey in 2010 [2], 90% of NHS radiology depart-
ments routinely perform BaF to investigate patients with
known or suspected CD, 80% perform CT, 56% USS and
38% MRI. Small bowel imaging tests differ in their indi-
vidual attributes; for example BaF affords high quality
assessment of the bowel mucosa, whilst cross sectional
techniques such as CT, MRE and USS facilitate evalu-
ation of the bowel wall and extra-enteric tissues. An im-
portant attribute is the use or otherwise of ionising
radiation. The currently most used tests, BaF and CT,
impart a significant radiation dose. This is concerning
given that CD patients are young and usually undergo
serial imaging to assess disease evolution over their life-
time. An audit in 2007 found 15.5% of CD patients re-
ceived a cumulative radiation dose that may increase
cancer risk by 7.3% [3]. USS and MRE are alternatives
that do not use ionising radiation but deployment in the
NHS is currently ad hoc. The choice of small bowelimaging investigation currently depends largely on non-
evidence based decision-making, such as clinician per-
sonal preference, perceived costs, available infrastructure
and radiological expertise.
Three systematic reviews have been published to date
evaluating the accuracy of imaging tests in the diagnosis
of CD and for assessing disease activity [4-6]. All have
highlighted marked heterogeneity in the available litera-
ture, with most studies being single centre and involving
relatively small patient numbers. Variation in the applied
standard of reference between studies is also apparent.
The largest systematic review [6] incorporated 68 stud-
ies, and compared the performance of CT, MRI and USS
for diagnosis, and disease activity classification. For diag-
nosis of disease location sensitivity of USS ranged from
75 to 93% and for MRI from 77 to 91%. Specificity
ranged from 98 to 100% (USS) and 60 to 100% (MRI).
The diagnostic accuracy to detect active disease per pa-
tient of studies USS sensitivity and specificity for detect-
ing active disease was 85% (range 75 to 100%) and 91%
(range 82-100%) respectively and for MRI were 80%
(range 78-100%) and 82% (range 46%-100%) respectively.
Only one study used the recommended direct diagnostic
test comparison study design shown to reduce bias by
assessing the same patients with multiple tests [7]. Miao
et al. [8] reported of sensitivity 87% for both USS and
MRI and specificities of 100% (7/7 patients) and 71% (5/
7 patients) respectively in a study with 30 patients (23
with Crohn’s and 7 with no disease) [8].
Ultimately, the optimal imaging strategy for CD remains
uncertain and single centre data is of limited utility. Un-
biased, robust data to inform the implementation strategy
for newer imaging technologies are currently unavailable,
although international guidelines on imaging advocate
MRE for diagnosis and USS for assessing disease activity,
where resource and expertise are available [9].
In this article, we describe the protocol for the METRIC
study (ISRCTN03982913), a multicentre, non-randomised,
single-arm, prospective comparison study of MRE and
USS in newly diagnosed CD, or established disease with
suspected relapse. The sample size of our study is ten
times larger than the only other study directly comparing
MRE and USS in the same patients (8). Participating ra-
diologists are members of BSGAR, British Society of
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this topic has been commissioned and funded by the UK
Health Technology Assessment (HTA) programme (11/
23/01). The full protocol adheres to the principals of the
SPIRIT guidelines for clinical trials protocols [10].
Study objectives
 Directly to compare the diagnostic accuracies of
MRE and USS for detecting small bowel CD, and
grading of inflammatory activity. This will include
subgroup analysis of patients with a new diagnosis
of CD and those suffering a relapse. The reference
standard consists of a consensus panel, with
collective review of all the available clinical and
imaging data over a 6-month follow up period.
 Directly to compare diagnostic accuracies of MRE
and USS for detecting colonic CD in those
undergoing colonoscopy.
 To use a novel trial design to reduce uncertainty in
evaluating the impact of MRE, USS and
conventional imaging methods by direct capture of
patient management.
 To evaluate the cost effectiveness of MRE and USS
compared to each other, and to conventional
imaging methods.
Methods
General
This is a multi-centre prospective cohort study compar-
ing the diagnostic accuracy of MRE and USS for the
presence, extent and activity of small bowel Crohn’s dis-
ease. The trial framework is to detect superiority of
MRE over USS (Figure 1).
Inclusions/exclusion criteria
The trial will recruit from two defined patient cohorts:
(1) newly diagnosed CD patients (or within 3 months of
diagnosis) and (2) those with previously confirmed CD
with a high clinical suspicion of luminal relapse, requir-
ing radiological investigation.
In the new diagnosis cohort, eligible patients are aged
16 years or older, have given written informed consent,
undergoing or having undergone colonoscopy, and either:
 Newly diagnosed (within 3 months) with CD based
on endoscopic, histological, clinical and radiological
findings, [11] or
 Highly suspected of CD based on characteristic
endoscopic, imaging and/or histological features but
pending final diagnosis.
In the suspected relapse cohort, eligible patients are
aged 16 years or older, able to give written informedconsent, with a known diagnosis of CD together with a
high clinical suspicion of luminal relapse defined as:
 Objective markers of inflammatory activity (raised
CRP >8 mg/L OR raised calprotectin > 100 mcg/g), or
 Symptoms suggestive of luminal stenosis (including
obstructive symptoms such as colicky abdominal pain,
vomiting) or abnormal endoscopy suggesting relapse.
Patients with any psychiatric or other disorder likely to
affect on informed consent and those with evidence of
severe or uncontrolled systemic disease, which at the
principal investigator’s discretion renders the patient un-
suitable for participation in the study, will be excluded.
Pregnant patients or those with contraindications to
MRE (e.g. allergy to all suitable contrast agents, cardiac
pacemaker, severe claustrophobia, or an inability to lie
flat) are also excluded. Recruited patients with suspected
disease whose final diagnosis is not CD, and those who
undergo surgical resection prior to colonoscopy will also
be excluded.
Ethical arrangements and consent
The METRIC trial achieved National Health Service re-
search ethics committee (NHS REC) approval in September
2013 (13/SC/0394) and is being conducted in accordance
with the principles of Good Clinical Practice (GCP). In-
formed consent is a prerequisite. University College
London’s Clinical Trials Unit supervises the trial.
Diagnostic interventions
MRE
Recruited patients will undergo MRE at their recruit-
ment site. The usual site radiographer team will perform
the examination providing they are deemed competent
by the site radiology lead.
The MRI platform (i.e. manufacturer and Tesla (T)
strength) will be decided by the local radiologist according
to scanner availability and usual practice. It is anticipated
most MRE will be performed at 1.5 T. Exact imaging pa-
rameters will vary according to MRI platform but a mini-
mum dataset of sequences will be acquired (Table 1). The
choice of oral contrast prior to MRE will also be according
to the usual practice of the recruitment site.
In some patients MRE will have been performed as
part of usual clinical care prior to recruitment. If it has
been acquired within the preceding 4 weeks according
to the minimum dataset of sequences, the MRE will be
eligible for inclusion in the trial and will not need to be
repeated.
USS
Recruited patients will also undergo small bowel USS
at their recruitment site. This will be performed by a
METRIC (MR Enterography or ulTRasound In Crohn’s disease)
Trial Flow Diagram 
167 Patients
Confirmed new diagnosis of Crohn’s disease OR
highly suspected based on colonoscopy/imaging
* IF MRE already performed pre recruitment-blinded radiologist review
If US already performed pre recruitment-repeated by blinded radiologist
167 Patients
Known Crohn’s disease with high clinical suspicion of 
relapse
334 Patients
-MRE and US performed by 2 blinded 
independent radiologists*
-blood and stool sample tests
-Repeat blood and stool sample tests 3 
months following instigation of therapy.
Discrepancy for the presence of non
contiguous small bowel disease proximal
to Terminal ileum on MRE and US
Additional small bowel 
investigation eg Capsule 
endoscopy, BaF, CT
Consensus panel composite reference standard for luminal disease presence, extent and
activity (based on all Ileo-colonoscopy, capsule endoscopy, imaging, histopathology, blood 
and stool test results) leading to a final therapeutic decision.
yes
no
Ileocolonoscopy (all
patients) & conventional
small bowel imaging (BaF,
CTE) if part of site standard
clinical practice
Total patient follow up 6 months-clinical  
course.  All standard clinical practice 
diagnostic tests recorded.
Figure 1 Flow diagram outlining the stages of the METRIC trial.
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tency criteria (see section below). For the purposes of
the trial, patients will not receive any oral agent before
the USS other than an optional 2 cups of water to
improve visualisation of the duodenum. The localradiologist will select the USS platform according to
scanner availability and usual practice. Exact imaging
parameters will vary according to USS platform but a
minimum probe frequency and examination technique
will be required (Table 2).
Table 1 MRE protocol outlining the minimum and
optional MRI sequences that may be performed
Minimum Coronal true FISP
Buscopan-20 mg IV
Axial and coronal non Fat Sat HASTE
Coronal Fat Sat HASTE
Axial diffusion b values 50 and 600
Coronal pre and post gadolinium T1 (60–70 sec)
Optional Axial True FISP
Axial Fat Sat HASTE
Axial post gadolinium T1
True FIP dynamic Motility
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repeated unless full blinding of the original performing
radiologist or sonographer to clinical and imaging data
can be assured.Other small bowel imaging
Many recruited patients will also undergo conventional
small bowel imaging as part of usual clinical care, not-
ably BaF, CT enterography and in some cases capsule
endoscopy. The results of these tests will provide at least
one independent small bowel imaging test for the con-
sensus reference standard for the proximal small bowel,
or non-endoscopically visualised terminal ileum.
In cases where the MRE and USS are discrepant for the
presence of disease and no other small bowel imaging has
been performed, a third arbiter test will be conducted. Dis-
crepancy will be defined as disagreement between MRE
and USS for the presence of disease in non-endoscopically
visualised terminal ileum, or for the presence of disease in
the proximal bowel upstream of the terminal ileum. The
choice of arbiter small bowel imaging test will be at the
discretion of the local recruitment site.Radiologist competence and training
A network of UK NHS hospitals with lead radiologists
affiliated to the British Society of Gastrointestinal andTable 2 USS imaging protocol
Preparation Nil by mouth- 4 hours
Technical
requirements
Use of both curve-linear and high resolution probe
(min 5 Mhz frequency)
Procedure Systematic review of colon and small bowel with
both probes
Review of enteric tissues
Application of colour Doppler (typical flow 6-9 m/s)Abdominal Radiology (BSGAR) will be used, ensuring
appropriate imaging expertise for the purposes of the
study.
All radiologists reporting on the trial are post-FRCR
with at least one year of sub-specialty GI experience.
They have previous experience of MRE and USS that
has been supplemented with a two-day training course
for the purposes of the study. Participating sonographers
will already be performing USS in clinical practice, hav-
ing attended a trial specific workshop and be deemed
competent by their supervising radiologist Trial centres
encompass both teaching and district general hospitals
to enhance generalisability.
Blinding of trial imaging
Unbiased estimates of imaging test diagnostic accuracy
can only be achieved if those interpreting the tests are
unaware of the findings of contemporaneous imaging
and endoscopy. For example a radiologist aware of endo-
scopically confirmed terminal ileal disease could not give
an unbiased evaluation of subsequent USS or MRE in
the same patient. Similarly, interpretation of MRE or
USS could be influenced by knowledge of the results of
the other test. Thus, detailed instructions for satisfactory
blinding of radiologists have been outlined in the proto-
col. Notably, both MRE and USS will be interpreted by
different radiologists blinded to all clinical information
other than the patient cohort (relapse or new diagnosis)
and surgical history. If blinding of the original reporting
radiologist cannot be assured, MRE images will be re-
analysed by a blinded local or central radiologist (as ap-
propriate), and USS will be repeated.
Reporting of trial imaging
A case report form (CRF) will be generated for MRE
and USS in all recruited patients. The CRF will detail
the technical quality of the examination, together with
the presence, extent and activity of Crohn’s disease. For
the purposes of data recording, the bowel will be divided
into duodenum, jejunum, ileum, terminal ileum and
colon (rectum, sigmoid, descending colon, transverse,
ascending and caecum). Colonic segments will be de-
fined using previously published definitions [12].
For each segment, radiologists will indicate the pres-
ence or absence of Crohn’s disease together with their
diagnostic confidence on a 6 point scale. Data on the
length of disease, activity, the presence of functionally
significant stenosis, and extra-enteric complications such
as abscess or fistulae will also be recorded. Standard def-
initions will be used for the identification of Crohn’s dis-
ease [13,14]. All distinct sections of disease in a segment
will be recorded separately.
Disease activity on MRE and USS will be assessed using
published validated criteria [13]. Reporting radiologists
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any disease present is active or non-active on a (per)
segment(al) and per patient basis. Reporting radiologists
will also record the impact of certain additional MRE
sequences, such as diffusion and contrast enhancement
to their decision making.
Experience questionnaires
Patients recruited prior to the MRE will be issued a
questionnaire pertaining to the acceptability of the oral
contrast preparation, immediately before the MRE, dur-
ing the test, and up to 48 hours later. Patients will be
questioned on their experience of other test facets such
as scanner noise.
A second questionnaire will be administrated to all re-
cruited patients and will assess comparative experience
and acceptability of MRE, USS and any other imaging
tests undergone during their clinical care.
Evaluating therapeutic impact
An assessment of the impact of MRE and USS on diag-
nostic confidence and patient management compared to
conventional imaging will be evaluated.
Gastroenterologists at each site will review the clinical
data and record their diagnostic confidence for the pres-
ence and location of CD, its activity, extra-enteric compli-
cations, need for additional investigations and planned
therapeutic strategy using a previously published proforma
[2]. A radiologist will then present the findings of one of
the imaging modalities (MRE, USS or more conventional
imaging such as CT, BaF (if performed), and the gastro-
enterologist will re-complete the proforma in light of these
imaging findings, noting changes (if any) in their diagno-
sis, diagnostic confidence or therapeutic decision. After
4 weeks, the process will be repeated, although the radi-
ologist will present another imaging modality. The order
of revelation of the imaging modalities for each individual
patient will be randomised centrally. The process will be
repeated until all 3 modalities have been revealed.
Reference standard
There is no single reference standard that can uniformly
be employed for the phenotyping of CD. Diagnosis and
phenotyping in clinical practice is made on a combin-
ation of clinical, endoscopic, imaging, histopathological
and biochemical criteria. The HTA has given guidance
regarding the evaluation of diagnostic tests when there
is no “gold standard” [15]. The current trial will use the
construct reference standard paradigm (panel diagnosis)
incorporating the concept of clinical test validation. Spe-
cifically patients’ clinical course will be followed for six
months after recruitment, during which time the find-
ings of the MRE and USS will have been acted upon byclinicians and incorporated into their therapeutic
decision-making.
Ileo-colonoscopy (combined with histological assess-
ment of tissue biopsies) is considered the most robust
standard of reference for diagnosis and phenotyping of
CD within the colon and terminal ileum (last few centi-
metres of small bowel). All newly diagnosed patients will
have undergone ileo-colonoscopy as part of their normal
clinical care.
Consenting patients will have their Harvey Bradshaw
index, plasma CRP and faecal calprotectin measured at
recruitment and after 3 months. These data will be made
available to the panel to provide an objective measure of
disease activity.
Each recruitment site will convene their own consen-
sus panel, to derive the reference standard for disease
presence, extent and activity at the time of the trial im-
aging in recruited patients. The panels will consider all
available clinical information including the results of
conventional investigations, endoscopy (conventional
and capsule), MRE, USS, surgical findings, histopath-
ology (surgical resection and biopsies), HBI, CRP, and
FC (and changes thereof in response to therapy), follow
up imaging and clinical course. Each panel will consist
of at least one (and ideally two) gastroenterologists and
two radiologists (one local to the site and one external).
A histopathologist will be available to the panel if re-
quired. When defining the reference standard for the
primary outcome, the panel will record their confidence
in the findings of each contributing test (e.g. all avail-
able imaging tests, endoscopy etc.) to allow assessment
of incorporation bias. Each panel will complete the final
reference standard CRF against which the diagnostic ac-
curacy of imaging tests will be compared.
Cost effectiveness
Resource use data for the main drivers of hospital costs
will be collected using a study-specific CRF. Additionally,
resource use diaries will be administered to all patients at
consent and then once more at 3 months. The diaries will
be used to collect data on primary and community care
contacts for the 6 month period of follow up from recruit-
ment. Economic costs associated with ultrasound and
MRE will be extrapolated.
Outcome measures
Primary outcome measure
Difference in per patient sensitivity between MRE and
USS for the correct identification and localisation of
small bowel CD.
The sensitivity of each test to detect presence of dis-
ease (both active and inactive disease) in the correct
location is measured against the reference standard,
consensus panel review at 6 months. There will be
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nosis versus relapse patients.
Secondary outcome measures
1. Difference in per patient specificity of MRE and USS
for the correct identification and localisation of
small bowel CD.
2. Comparison of USS and MRE detection of patients
with active small bowel CD.
This will include:
a. Difference in sensitivity and specificity per patient
based on a consensus
review as a reference standard
b. Difference in sensitivity and specificity in the
terminal ileum in those patients undergoing
terminal ileostomy as a reference standard
c. Additional analysis for colonic segments in
patients with a colonoscopic reference
examination
3. Comparison of USS and MRE diagnostic accuracy to
detect presence of disease (either active or inactive)
a. Difference in sensitivity and specificity per patient
in small bowel and colonic CD
b. Difference in sensitivity and specificity of terminal
ileum segment in subgroup of patients
undergoing colonoscopy in small bowel and
colonic CD
c. Difference in sensitivity and specificity per
segment in subgroup of patients undergoing
colonoscopy in colonic CD
d. Subgroup analysis of (i) and (ii) in patients with
small bowel only
4. Comparative impact of MRE and USS on clinician
diagnostic confidence for the presence of CD and
influence on patient management
5. The lifetime incremental cost and cost-effectiveness
of assessment using MRE or USS
For the above there will be subgroup analysis for
separate populations of new diagnosis versus relapse
patients.
In addition several substudies are planned including
1. Diagnostic accuracy and radiologist confidence using
hydrosonography compared to conventional USS
2. Comparative patient experience of MR and USS
3. Diagnostic impact of novel MRE sequences, notably
diffusion weight imaging on disease detection,
diagnostic confidence and disease activity
assessment
4. Inter-observer variation in the evaluation of MRE
and USS datasets by radiologists, to assess the
impact of diagnostic confidence on accuracySample size
Power is based on the primary outcome stipulated by the
HTA: diagnostic accuracy for CD extent. There are two
aspects to correctly assigning disease extent; correctly de-
tecting the presence of disease and correctly assigning its
segmental location. For example a test which correctly
identifies disease in the terminal ileum of the small bowel,
but misses disease in the proximal bowel (e.g. jejunum)
will conceivably result in an incorrect patient management
decision i.e. such a test would be inaccurate for defining
the extent of CD. Power is thus based on a two facetted
compound accuracy measure (disease presence and dis-
ease location) [4,16,17].
A total cohort of 301 (210 patients with disease) is re-
quired to detect a 10% superiority of MRE over USS in
correctly assigning disease presence and location at 90%
power (type 2 error) [18]. Allowing 10% loss to follow up
(referring to patients who fail to undergo the complete set
of initial imaging – colonoscopy, ultrasound and MRI for
new diagnosis patients and ultrasound and MRI for re-
lapse patients – currently this lies at 12%), the total cohort
is of 334 patients (167 new diagnosis patients and 167 re-
lapse patients).
Analysis
A detailed statistical analysis plan will be produced and
finalised prior to data lock and transfer to trial statisti-
cian. Analysis will be based on all patients in the study.
The primary and secondary outcomes will be based on
available case analysis with a sensitivity analysis using
multiple imputations, best case and worst case analysis.
Analysis for the primary outcome will use logistic re-
gression of paired binary outcomes for comparison of
diagnostic accuracy measures of MRE and USS within
patients, allowing adjustment for clustering by centre.
95% confidence intervals will be calculated and p-values
of <0.05 will be considered statistically significant. A simi-
lar approach will be used for the secondary outcomes.
There will be no adjustment of p-values for secondary
outcomes for multiple testing. STATA statistical software
will be used.
Discussion
Blinding of trial imaging
Ascertaining the true standalone diagnostic accuracy of an
individual imaging test is only possible in the absence of
external influences to radiological decision making. Inter-
pretation of MRE or USS is likely to be influenced by
knowledge of clinical parameters and findings of other im-
aging tests. The study methodology has therefore been
specifically designed to ensure strict blinding of the radiol-
ogists. Radiologists’ information is restricted to the patient
cohort (new diagnosis or relapse), and the history of previ-
ous surgery; this information would be available in usual
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clinical practice. Each recruitment site has identified two
participating radiologists so the MRE and USS for each re-
cruited patient can be conducted and interpreted by an in-
dependent radiologist. Trial MREs will be reviewed on
workstations separate from the hospital reporting plat-
forms, to ensure blinding from other imaging or reports.
Similarly, during USS, where interpretation is more “real
time”, the radiologist performing USS will be isolated from
all material usually available in the clinical setting. The pa-
tient and the radiologist will be advised not to converse
with the patient regarding current diagnosis during the
USS and where feasible the patient will accompanied by
the research nurse during the USS.
For those patients who underwent an MRE prior to re-
cruitment, their images will be re-evaluated by an alter-
nate radiologist, blinded to other patient information.
For patients who underwent an USS prior to recruit-
ment, their USS will be repeated by an alternate radiolo-
gist (unless appropriate blinding of the radiologist
performing the original USS can be assured).Consensus panel as reference standard and assessment of
incorporation bias
There is no single test proven to be a reference standard
in the diagnosis of disease presence, extent and activity
in CD within the small bowel. In such cases, a consensus
panel may be convened to judge the presence or absence
of the target condition based on multiple sources of in-
formation, as recommended by the HTA [15].
There is significant variation in the construct and be-
haviour of consensus panels. A recent systematic review
of published methods and reporting of studies using ex-
pert panels to define the reference standard in diagnostic
studies provides recommended options for consensus
panels composition, decision making and reporting [19].
One such crucial point is whether or not to incorporate
the index tests, MRE and USS, in the consensus review.
Inclusion of the index test result may overestimate its
importance, leading to incorporation bias, and falsely
high accuracy. Conversely, excluding the index test may
hamper the ability to make the correct diagnosis, result-
ing in misclassification of the disease status. Several
staged approaches have been proposed, such as those in
which the panel forms an opinion without the index
tests and these are then revealed for review and a final
decision is reached. Such approaches are time and
personnel intensive and deemed impractical on such a
large scale. In order to minimise incorporation bias, the
expertise of all panel members will be recorded as well
as the level of consensus reached (majority or unani-
mous) for the primary outcome. The panel may request
review by a second independent panel if they are unableto reach consensus on the primary outcome reference
standard (presence and location of small bowel CD).
When defining the reference standard for the primary
outcome, the panel will record their confidence in the
findings of each contributing test (e.g. all available imaging
tests, endoscopy etc.). Specifically they will state if the nor-
mality or otherwise of each available test is clear cut or
equivocal. Such data will help detect potential incorpor-
ation bias (e.g. if an equivocal MRI “overrides” a clear cut
CT enterography and USS). The trial statistician and CI
will review the outcome of the panel review for the first
50 recruited patients centrally. If incorporation bias is
deemed problematic, a decision will be made as to the
need for a routine second panel review of cases when the
findings of tests contributing to the primary outcome ref-
erence are discrepant.
To standardise the decisions of the consensus panel a
member of the central trial team will attend each con-
sensus meeting to ensure similar criteria are used in de-
fining disease extent.
The METRIC trial is a multi-centre prospective cohort
study comparing the diagnostic accuracy of MRE and USS
for the presence, extent and activity of small bowel
Crohn’s disease. The lack of a single reference test has led
to the use of a consensus panel to act as the reference
standard, with specific attention to minimize incorpor-
ation bias. The trial methodology includes detailed proto-
cols in order to ensure adequate blinding of radiologists.
In addition the trial includes direct recording of patient
management decisions resulting from MRE and USS test
results, to reduce uncertainty in evaluating the compara-
tive impact of modalities. The sample size of our study is
ten times larger than the only other study directly compar-
ing MRE and USS in similar patients (8).
Trial status
The trial was launched at the main site University College
Hospital (London) (UCH) on the fourth of December
2013 and is currently recruiting at five centres – UCH,
Leeds Teaching Hospitals, Ninewells Hospital (Dundee),
Northwick Park and St Mark’s Hospitals, Oxford Univer-
sity Hospitals, Queen Alexandra Hospital (Portsmouth).
Other sites are currently undergoing site-specific initia-
tions. The trial has recruited 46 patients – 14 in the New
diagnosis arm and 32 in the relapse arm.
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